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Summary
PROBLEM: Given the important role of regulatory T cells
(Treg) for successful pregnancy, the ability of soluble ma-
ternal and fetal pregnancy factors to induce human Treg
was investigated.
METHOD OF STUDY: Peripheral blood mononuclear
cells (PBMCs) or isolated CD4+CD25‒ cells were cultured
in the presence of pooled second or third trimester preg-
nancy sera, steroid hormones or supernatants from pla-
cental explants, and the numbers and function of induced
CD4+CD25+FOXP3+ Treg were analysed.
RESULTS: Third trimester pregnancy sera and super-
natants of early placental explants, but not sex steroid hor-
mones, induced an increase of Tregs from PBMCs. Early
placental supernatant containing high levels of tumour nec-
rosis factor-α, interferon-γ, interleukins -1, -6 and -17, sol-
uble human leucocyte antigen-G, and transforming growth
factor-β1, increased the proportion of Treg most effectively
and was able to induce interleukin-10-secreting-Treg from
CD4+CD25‒cells.
CONCLUSIONS: Compared with circulating maternal
factors, placental- and fetal-derived factors appear to exert
a more powerful effect on numerical changes of Treg,
thereby supporting fetomaternal tolerance during human
pregnancy.
Key words: human regulatory T cells; cell expansion;
human serum; placenta
Introduction
Successful pregnancy is a challenge for the maternal im-
mune system. Tolerance mechanisms have to become op-
erative in order to protect the semiallogeneic fetus against
immune attacks from the mother. Among the factors or-
chestrating tolerance during pregnancy, regulatory T cells
(Treg) play a pivotal role [1]. The development and func-
tion of the Treg lineage depends on the expression of the
transcription factor forkhead box P3 (FOXP3). In humans,
about 1%–2% of T helper cells (CD4+ T cells) in the peri-
pheral blood are Treg [2]. They originate in the thymus
as naturally occurring Treg and can also be induced in
the periphery from CD4+CD25‒ cells under certain condi-
tions, including T cell receptor-mediated stimulation, tol-
erogenic dendritic cells, human leucocyte antigen-G
(HLA-G) or transforming growth factor-beta (TGF-β)
[3–5]. The suppressive activity of Treg is mediated either
in a cell-cell contact mediated fashion via cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) or by the secre-
tion of cytokines such as TGF-β or interleukin (IL)-10 [6,
7].
During normal murine pregnancy, the pool of Treg cells
expands locally at the fetomaternal interface and system-
ically compared with nonpregnant mice [8]. Treg cells ex-
posed to paternal antigens suppress maternal alloresponses
to protect against fetal rejection, whereas in miscarriage-
prone mice the number and function of Treg are diminished
[8, 9]. Similar to the animal data, studies performed in hu-
man pregnancy have shown an expansion of Treg at the
fetomaternal interface, resulting in higher percentages of
Treg at the decidual level compared with those in the peri-
pheral blood [10, 11]. Moreover, reduced local Treg levels
are associated with pregnancy pathologies such as spontan-
eous abortion [10]. In human peripheral blood, however,
the frequency of Treg varies depending on how these cells
are characterised by means of flow cytometry. If Treg are
defined as CD4+CD25+ T cells, which includes Treg and
activated T cells, there is an increase of these cells during
normal human pregnancy, peaking in the second trimester
and decreasing after delivery [12]. By contrast, when Treg
are defined as CD4dimCD25high cells or as
CD4+CD25+FOXP3+CD127‒ cells the frequency of cir-
culating Treg during pregnancy is unaltered or even dimin-
ished [13, 14].
In regard to the mechanisms that play a role in Treg
expansion during pregnancy different factors have been
investigated. The hormones oestradiol and progesterone,
which increase markedly during gestation, have been sug-
gested as possible explanations for the pregnancy-related
Treg expansion [15, 16]. Other important factors that con-
tribute to Treg expansion during gestation are fetal anti-
gens. Until now, the expansion of Treg specific to fetal
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antigens and its importance in a successful allogeneic
pregnancy have mainly been shown in the mouse model
[8, 17, 18].
In this study we aimed to investigate the nature of factors
contributing to the numerical changes of human Treg cells
during gestation. By exposing peripheral blood mononuc-
lear cells (PBMCs) and isolated CD4+CD25- T cells from
nonpregnant healthy women to pregnancy sera and super-
natants of placental tissue, the abilities of maternal and
fetal factors to induce numerical changes of Treg were
compared.
Materials and methods
Collection of peripheral blood and serum samples
The recruitment of healthy women and the experimental
design were approved by the Ethics Board of the Canton
of Bern. Blood samples and placental tissue were obtained
after informed consent of the participating women.
Heparinised venous blood or buffy coat from female blood
donors was obtained from 24 healthy, nonpregnant women
aged between 25 and 45 years. All donors were
nonsmoking healthy volunteers working in the Inselspital
and taking neither hormonal contraceptives nor any other
medication.
Human AB serum was obtained from the Swiss blood bank
in Bern. The autologous donor serum was obtained from
venous blood. Serum samples from pregnant, healthy wo-
men – who had been recruited in a cross-sectional manner
at the second trimester (n = 10, gestational weeks 14–24)
and at the third trimester (n = 10, gestational weeks 26–34)
– were pooled and stored at –20 °C until further use.
Four first trimester placentas (gestational weeks 7–12)
were obtained from electively aborted fetuses of healthy
women who had opted for pregnancy termination for
psychosocial reasons. Four term placentas were obtained
from healthy women (range, gestational age week 37–40)
after normal pregnancy and vaginal delivery.
Figure 1
Pregnancy sera and placental factors augment the proportion
of regulatory T (Treg) cells among peripheral blood
mononuclear cells.
Effect of pregnancy sera and supernatant from early placental
explants on the percentage of CD4+CD25+ T cells (A) or
CD4+CD25+FOXP3+ T cells (B) among peripheral blood
mononuclear cells from healthy women (n = 4). Data are expressed
as boxplots with whiskers from minimum to maximum; the statistical
analysis was performed using the Wilcoxon signed rank test. An
asterisk indicates p <0.05.
Control = nonpregnant human serum; PS2 = pooled second
trimester pregnancy sera; PS3 = pooled third trimester pregnancy
sera; Plac = supernatant from early placental explants
Isolation of early and term placental explants and
preparation of placental supernatant
Placental villi from early and term placenta tissue samples
(2 x 2 cm in size) were dissected into 2–4 mm3 fragments
free of visible vessels and washed three times in sterile
PBS to remove blood cells. The explants were cultured
in 10-cm diameter dishes precoated with collagen type
1 (BD Bioscience) in DMEM/F12 nutrient mixture 1:1
(Gibco, USA) supplemented with 15% KnockOut serum
replacement (Gibco, USA), 1% Glutamax and antibiotic/
antimycotic solution (Invitrogen, CA, USA). The explants
were incubated in a 95% humidified atmosphere at 37
°C and comprising 5% CO2. After adherence of the ex-
plants (after 5–7 days) to the culture dish, the culture me-
dium was changed and collected every 3 days for 2 weeks.
After collection the supernatant was immediately stored
at –20 °C. The collected and pooled placental supernatant
from each sample was concentrated 10X using sterilised
Vivaspin ultracentrifugation tubes (Sartorius Stedim Bi-
otech, Germany) with a 5kDa filter cut-off. It was then
stored in 1 ml aliquots at –20 °C until further use.
Antibodies used for flow cytometry
For cell surface staining, anti-CD3 PE (clone HIT-3A);
anti-CD4 PerCP (clone SK3), anti-CD25 APC and anti-
CD25PE (clone 2A3) were used (all from BD Biosciences
Pharmingen, USA). For the intracellular staining, anti-Fox-
p3 FITC and APC (clone PCH101) were utilised with the
eBioscience Fix/Perm Buffer kit. After surface and intra-
cellular staining of PBMCs and sorted cells, acquisition
was done through FACs Calibur (BD;USA) and analysed
using Flowjo software (Treestar, USA). Cells were gated
on CD4+ T cells.
Figure 2
Induction of regulatory T (Treg) cells from CD4+CD25‒ T cells.
FACS staining after cell sorting. Cells are gated on CD4+ cells. The
upper plot shows CD4+CD25‒FOXP3‒ T cells that were used at
day 0 for the induction assay. The lower plot shows the induction of
CD4+CD25+FOXP3+ cells after 3 days’ exposure to supernatant
from early placental explants (A). Effect of pregnancy serum and
supernatant from early or term placental explants on the
percentage of CD4+CD25+ T cells (B) and CD4+CD25+FOXP3+ T
cells (C) in cell cultures with sorted CD4+CD25‒ T cells from
healthy women (n = 6; for cultures with term placenta n = 2). Data
are expressed as boxplots with whiskers from minimum to
maximum and statistical analysis was performed using Wilcoxon
signed rank test. An asterisk indicates p <0.05.
Control = nonpregnant human serum; PS3 = pooled third trimester
pregnancy sera; Plac early = supernatant from early placental
explants; Plac term = supernatant from term placental explants
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Cell culture, generation of regulatory T cells and
suppression assay
PBMCs were isolated from either heparinised venous
blood or buffy coats through density gradient centrifuga-
tion using Histopaque-1077 (Sigma Aldrich Company, St.
Louis, MO, USA). After washing, PBMCs were cultured in
RPMI-1640 (Invitrogen, CA, USA) supplemented with 1%
sodium pyruvate, 1% nonessential amino acids, 1% kana-
mycin and 1% glutamax at 37 °C with 5% CO2. Cells were
cultured in the presence of 10% nonpregnant human serum,
10% pregnancy serum, or 10% of supernatant from early or
term placental explants. Hormones at pregnancy levels (10
ng/ml of 17β-oestradiol, 10 ng/ml of oestriol, 200 ng/ml
of progesterone; all hormones were from Sigma Aldrich)
or recombinant human TGF-β1 (R&D systems, UK) were
separately added to the culture medium supplemented with
nonpregnant human serum.
In order to induce Treg from PBMCs, isolated PBMCs (1
x 106 cells) were cultured for 3 days in the presence of
the aforementioned different pooled sera or placental su-
pernatants, as well as in the presence of hormones or re-
combinant TGF-β1. In all experiments with PBMCs, 10 IU
of recombinant human IL-2 (R&D systems, UK) were ad-
ded.
In order to induce Treg from CD4+CD25‒ T cells,
CD4+CD25‒ T cells were sorted by use of flow cytometry
(FACS Aria, Becton and Dickinson) and cultured (1 x 106
cells) for 3 days in the presence of the aforementioned dif-
ferent pooled sera, placental supernatants and hormones.
For polyclonal activation, CD4+CD25‒ T cells were cul-
tured with 1 μg/ml of plate-bound anti-CD3 (clone OKT-3),
5 μg/ml of anti-CD28 (BD Biosciences; USA) and 10 IU of
recombinant human IL-2.
The percentages of CD4+CD25+ T cells and
CD4+CD25+Foxp3+ T cells in the induction assays were
analysed by means of flow cytometry.
Treg induced from sorted CD4+CD25‒ T cells as described
above were further investigated in a suppression assay.
First, induced Treg were isolated using the
CD4+CD25+CD127dim isolation kit (Miltenyi Biotec, Ger-
many). CD4+CD25‒ T cells were isolated from PBMCs
from the same donor using CD4 and CD25 microbeads
(Miltenyi Biotec, Germany). Isolated CD4+CD25‒ and
CD4+CD25+CD127dim Treg (25,000 cells : 25,000 cells)
were cultured alone or co-cultured in a 1:1 ratio and stim-
ulated with 1 μg/ml immobilised anti-CD3 and 5 μg/ml
of anti-CD28. After 72 hours, H3-thymidine was incorpor-
ated, and the cells were harvested after 18 hours in order to
measure cell proliferation. The percentage of suppression
was calculated by use of the following formula: 1 ‒ (cpm
incorporated in the cocultured cells / cpm of CD4+CD25‒
cells cultured alone) x 100.
Cytokine profile and HLA-G
The cytokine concentration in pooled pregnancy sera,
pooled nonpregnant sera, pooled placental supernatants,
and supernatants from the induction assays was analysed
for tumour necrosis factor-α (TNF-α), interferon-γ (IFN-γ),
IL-1, IL-6, IL-17 and IL-10 using a customised bioplex as-
say (Bio-Rad Laboratories, CA, USA). The samples were
prepared and run according to the manufacturer’s protocol,
then read and analysed using the Bioplex manager software
(Bio-Rad).
TGF-β1 and soluble HLA-G were measured in the samples
described above by use of sandwich enzyme-linked im-
munosorbent assay. For TGF-β1, the detection and capture
antibodies were obtained from BD Biosciences. The re-
combinant human proteins used for the standard curve
were obtained from R&D systems UK. The nonclassical
major histocompatibility complex class I molecule HLA-
G was determined using sHLA-G kit (Biovendor, CZ) ac-
cording to the manufacturer’s protocol. The samples were
read at 450 nm using Spectramax 190 and analysed using
Softmax Pro software.
Statistical analysis
Significant differences of related samples were calculated
using the nonparametric Wilcoxon signed-rank test. For all
tests a significance level of p <0.05 was applied.
Results
Effect of pregnancy sera and placental supernatant on
the proportion of Treg
We first determined whether soluble pregnancy factors are
able to increase the percentage of CD4+CD25+FOXP3+
Treg in PBMCs of nonpregnant, healthy women. Cells
were cultured in the presence of pooled sera from the
second or third trimester of normal pregnancy, representing
mainly the sum of maternally derived pregnancy factors,
or in the presence of filtered supernatant from early pla-
cental explants, representing mainly fetal factors. The ana-
lysis showed that pregnancy sera and placental supernatant
induced a slight, insignificant, increase in the percentage of
CD4+CD25+ activated T cells (fig. 1A). However, the per-
centage of Treg rose significantly in the presence of third
Figure 3
Effects of hormones on the proportion of regulatory T cells
(Treg).
Effect of 17-oestradiol, oestriol and progesterone used at
pregnancy levels on the proportion of Treg among PBMC (A) and
CD4+CD25‒ T cells (B) from healthy women (n = 4). Data are
expressed as boxplots with whiskers from minimum to maximum
and statistical analysis was performed using Wilcoxon signed rank
test.
Control = non-pregnant human serum; 17-Estrad = 17β-oestradiol;
Prog = progesterone; 17-Estrad/Prog = combination of 17β-
oestradiol and progesterone; PBMC = peripheral blood
mononuclear cell
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trimester pregnancy sera (p = 0.028) and early placental su-
pernatants (p = 0.018) (fig. 1B).
We then investigated the induction of Treg from isolated
CD4+CD25‒ T cells (fig. 2A, upper panel), which were ex-
posed separately to three different conditions: pregnancy
sera, supernatant from early placental explants, and super-
natant from term placental explants. After 3 days, both
the percentage of induced CD4+CD25+FOXP3+ Treg
(fig. 1A, lower panel) and the percentage of activated T
cells (CD4+CD25+) were analysed. No difference in the
percentage of activated T cells was observed (fig. 2B). By
contrast, the percentage of CD4+CD25+FOXP3+ cells was
significantly higher among cells cultured in the presence of
supernatant from early placental explants than among those
cultured in control sera (p = 0.028) or third trimester sera
(p = 0.028) (fig. 2A lower panel and fig. 2C).
Analysis of single factors of pregnancy sera and
placental supernatants
Since pregnancy is associated with a marked increase of
sex steroid hormones in the maternal circulation, the effect
of 17β-oestradiol, oestriol and progesterone on the propor-
tion of Treg was analysed. Though the hormones were ap-
plied at concentrations found during the third trimester,
there was no effect on the percentage of Treg (fig. 3),
neither in cultures with PBMC nor in cultures with isolated
CD4+CD25‒ T cells.
Furthermore, pregnancy serum and supernatant from pla-
cental explants were analysed for factors that could play a
role in cell activation and induction or expansion of Treg
(table 1). Unlike the control sera and third trimester preg-
nancy sera, supernatant of early placental explants con-
tained substantial amounts of proinflammatory cytokines
such as TNF-α, IFN-γ, IL-1, IL-6 and IL-17 and showed
the highest levels of soluble HLA-G. In addition, both su-
pernatant of early placental explants and pregnancy sera
displayed elevated levels of active TGF-β1. In contrast to
supernatant of early placental explants, supernatant of term
placental explants showed lower levels of TGF-β1 and
Figure 4
Transforming growth factor-β (TGF-β) increases the proportion
of regulatory T cells (Treg).
Displayed is the effect of increasing doses of TGF-β1 on the
percentages of CD4+CD25+FOXP3+ and CD4+CD25+FOXP3- T
cells among PBMC of healthy women (n = 2). Data are expressed
as dots, error bars representing mean ± SEM.
Control = nonpregnant human serum
lower levels of sHLA-G but higher levels of TNF-α and of
IL-6. Interestingly, TGF-β1 concentrations at levels present
in sera of the third trimester and in supernatants of early
placental explants were able to augment the proportion of
Treg in a dose-dependent manner (p <0.05 for the differen-
ce between CD4+CD25+FOXP3+ cells in control medium
or with 1 ng/ml TGF-β1, fig. 4).
Cytokine secretion and suppressive function of
regulatory T cells induced from the pool of
CD4+CD25‒ T cells
To analyse the function of Treg induced from isolated
CD4+CD25‒ T cells, the cell culture supernatants were
analysed for various secreted cytokines. Proinflammatory
cytokines such as IFN-γ, TNF-α and IL-17 could be de-
tected in similar amounts in cell cultures exposed to each
control sera, pregnancy sera, and the supernatant of pla-
cental explants (fig. 5 A–C). In contrast, the concentration
of IL-10 was significantly elevated in the culture super-
natants of Treg induced in the presence of supernatant of
early placental explants relative to cultures in pregnancy
sera (p = 0.046) or control sera (p = 0.046) (fig. 5D). Thus,
the elevated amounts of IL-10 corresponded to the in-
creased percentage of Treg induced in cell cultures of
CD4+CD25‒ T cells which were exposed to supernatants
of early placental explants.
Next, we analysed the suppressive function of induced
Treg that were generated in the induction assay from sorted
CD4+CD25‒ T cells of nonpregnant healthy women. As
shown in figure 6, isolated Treg, defined as
CD4+CD25+CD127low cells, that were induced in the pres-
ence of pregnancy serum or supernatant of early placental
explants were able to suppress the proliferation of autolog-
ous CD4-CD25‒ T effector cells (mean suppression rates:
97% with control sera, 62% with pregnancy sera, 51% with
placental supernatant).
Discussion
Our study shows that factors present in the maternal cir-
culation during pregnancy and in the placenta augment the
proportion of CD4+CD25+FOXP3+ T cells that show a
cytokine profile and suppressive activity characteristic of
regulatory T cells. By analysing the effects of pregnancy
serum and supernatant of placental explants on numerical
changes of Treg, we compared the relevance of maternal
versus fetal factors. We showed that supernatant of early
placental explants was the most powerful factor, since it
generated increased percentages of Treg not only from
PBMCs but also from isolated CD4+CD25‒ T cells. By
contrast, pregnancy serum containing predominantly ma-
ternal pregnancy factors was able to increase the percent-
age of Treg among PBMC, but had no effect on the induc-
tion of Treg from isolated CD4+CD25‒ T cells.
The effect of pregnancy serum was likely related to the in-
creased concentration of TGF-β1, but not related to oestro-
gen or progesterone. This contradicts previous studies that
found an increase in Treg both in mice treated with oestro-
gen and in human male CD4+CD25+ cells cultured with
pregnancy doses of oestradiol combined with activation
through CD3/CD28 [15, 16]. Differences in study design
Original article Swiss Med Wkly. 2015;145:w14172
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and in the culture conditions may account for the disagree-
ment. To detect the effect of hormones on Treg expansion,
a longer culture duration or a different stimulation modus
than used in our study might be necessary.
Even though fetal antigens are released into the maternal
circulation during pregnancy, the placenta remains the
main source of fetal antigens [19]. In our study, super-
natants of early placental explants served as a source of
fetal antigens. The measurement of soluble HLA-G, which
is primarily derived from fetal trophoblast cells [20], was
used to demonstrate the prominence of fetal antigens in
placental supernatants as compared with pregnancy sera or
sera of nonpregnant women. Fetal antigens are the most
Figure 5
Cytokine secretion of regulatory T (Treg) cells induced by
pregnancy serum or placental supernatant.
Cytokine concentrations (picograms per millilitre) in culture
supernatants of Treg induced from sorted CD4+CD25‒ T cells of
healthy donors in the presence of pregnancy serum or supernatant
from early or term placental explants. Statistical analysis was
performed using Wilcoxon signed rank test. Asterisk indicates p
<0.05.
Control = non-pregnant human serum, PS3 = pooled third trimester
pregnancy serum; Plac-early = supernatant of early placental
explants; Plac-term = supernatant of term placental explants: IFNγ
= interferon-γ; IL = interleukin; TNFα = tumour necrosis factor-α
relevant factors driving the expansion of fetus-specific
Treg that accumulate in the placenta during murine preg-
nancy and even persist after delivery [18, 21]. In contrast
to thymus-derived Treg, these peripherally induced fetus-
specific Treg are essential for successful pregnancy and are
regulated by a conserved noncoding DNA sequence of the
foxp3 locus, namely CNS 1 [21]. CNS1 contains binding
sites for the Smad3 protein which are activated by TGF-
β underlining the importance of this particular cytokine
for the differentiation of peripheral Treg from CD4+CD25-
naïve T cells [21, 22]. Hence, fetal antigens and TGF-β are
important for the expansion of peripheral Treg during preg-
nancy. High levels of TGF-β produced by trophoblast cell
lines were recently found to be an important factor for the
induction of Treg from CD4+CD25- T cells [23]. Our ana-
lysis showed that both pregnancy serum and supernatant
of placental explants contained similar concentrations of
TGF-β, yet only placental supernatant was able to gener-
ate CD4+CD25+FOXP3+ Treg from isolated CD4+CD25‒
T cells. Our data therefore support the Treg-inducing/ex-
panding effect of additional factors such as fetal antigens,
Figure 6
Suppressive function of regulatory (Treg) T cells induced by
soluble pregnancy factors.
Treg cells induced from CD4+CD25‒ T cells (iTreg) of two healthy
donors in the presence of different soluble pregnancy factors were
isolated and used in a co-culture suppression assay with
autologous CD4+CD25‒ T cells (Teff). iTreg and Teff cells cultured
alone or in a 1:1 setting were analysed for proliferation and for the
suppressive capacity of Treg. Data are expressed as mean ± SEM.
Control = nonpregnant human serum; PS3 = pooled third trimester
pregnancy serum; Plac = supernatant of early placental explants.
Table 1: Cytokines and soluble HLA-G in sera and placental supernatant.
Control sera+ Pregnancy sera Placental supernatants Placental supernatant
3rd trimester++ Early* Term*
TNF-α (pg/ml) Below** Below** 344.5 666.6
IFN-γ (pg/ml) Below** Below** 2692.8 1120.4
IL-1 (pg/ml) Below** Below** 3.6 7.6
IL-6 (pg/ml) 0.05 0.05 2769.7 4338.1
IL-17 (pg/ml) Below** Below** 153.5 29.8
IL-10 (pg/ml) Below** Below** 2.1 1.5
TGF-β1 (pg/ml) 7.3 971.3 865.9 287
sHLA-G (U/ml) 22.7 73.6 270.4 11.8
+ Pooled female non-pregnant sera
++ Pooled third trimester pregnancy sera
* Mean of two supernatants from early or term placental explants
** Below = below detection limit
IFN-γ = interferon-gamma; IL-6 = interleukin 6; sHLA-G = soluble human leucocyte antigen-G; TGF-β1 = transforming growth factor-beta1; TNF-α = tumour necrosis factor-
alpha
Original article Swiss Med Wkly. 2015;145:w14172
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 5 of 11
which are more prevalent in placental supernatant than in
pregnancy serum.
In the comparison of supernatants from early versus term
placental explants, a significant increase of Treg from sor-
ted CD4+CD25‒ T cells could be detected only in cultures
with supernatant from early placental explants. This phe-
nomenon might be due to the fact that HLA-G as a marker
of extravillous trophoblast cells (EVT cells) is abundantly
expressed by first trimester placenta, because EVT cells are
important for appropriate trophoblast invasion into decidu-
al intersitium and spiral arteries in successful pregnancy
[24]. During the course of pregnancy, in particular in the
third trimester, HLA-G-expressing EVT cells and soluble
HLA-G decrease significantly [25, 26].
Therefore, the larger proportion of HLA-G-expressing
EVT cells in first trimester placental explants relative to
term placental explants might be responsible for the more
powerful Treg expansion by the supernatant of early pla-
cental explants. In addition, the placental protein 14, also
known as glycodelin, is found in higher concentrations in
the first trimester decidua than in late pregnancy decidua
[27]. This placental glycoprotein has been shown to expand
Treg cells and could therefore be an additional factor for
the more pronounced effects of supernatant from early pla-
cental explants [28].
In contrast to pregnancy serum, supernatant of early pla-
cental explants contained both anti- and proinflammatory
cytokines. This mirrors the cytokine milieu present at the
fetomaternal interface during early normal pregnancy and
underlines the fact that that a certain amount of inflam-
mation is necessary for successful placentation [29–31].
Proinflammatory cytokines do play a role in cell activation
as well as in the development of INFγ and TNF-α secreting
Th1 cells or IL-17-secreting Th17 subsets [32, 33]. On the
other hand, it has been shown that proinflammatory cy-
tokines such as IL-6 and TNF-α render T effector cells res-
istant to the suppressive activity of Treg [34]. However,
during pregnancy pro- and anti-inflammatory cytokines
need to be well balanced since a predominance of either
Th1 cells or Th17 cells has been associated with recurrent
miscarriage or pre-eclampsia [35]. Compared with third
trimester sera or nonpregnant sera, supernatant of early
placental explants did not induce an increase of activated
CD4+CD25+ T cells, Th1 cells or Th17 cells, but rather
augmented the percentage of CD4+CD25+FOXP3+ Treg
cells. This predominance of Treg is of interest, since the
cytokines IL-1β and IL-6 present in supernatant of early
placental explants are known to be required for the differ-
entiation of human Th17 cells [36]. However, elevated con-
centrations of TGF-β inhibit the development of Th17 cells
and promote the induction of Treg [37].
In our experiments with PBMC, an increase in the per-
centage of Treg could be seen in cell cultures stimulated
with 10 IU IL-2 and exposed to either third trimester preg-
nancy sera or supernatant of early placental explants. In
these PBMC cultures, antigen-presenting cells (APCs), in-
cluding dendritic cells and macrophages, could play an im-
portant role in Treg cell induction and expansion as shown
by others [38, 39]. In this respect, HLA-G and cytokines
such as IL-10, TGF-β, and IFN-γ are among the factors that
induce tolerogenic APCs [5, 40, 41]. During human preg-
nancy, tolerogenic APCs emerge especially at the fetoma-
ternal interface, facilitating the induction and expansion of
Treg [42]. One important mechanism by which tolerogenic
monocytes from first trimester decidua induce Treg is the
expression of indoleamine 2,3-dioxygenase [43].
The main limitation of our study is the small sample size.
The representative character of our findings might there-
fore be limited. However, recent findings about the signi-
ficance of human placental-derived factors for the expan-
sion of Treg support our results [44].
In conclusion, it appears in our study that a combination
of cytokines and fetal antigens present in supernatant of
first trimester placental explants showed the most powerful
impact on the frequency of CD4+CD25+FOXP3+ Treg
cells, whereas maternal circulating factors were less effect-
ive. However, extended studies are needed to clarify which
placenta-derived molecules exert antigen-specific Treg ex-
pansion and function, thereby supporting fetomaternal im-
mune tolerance during human pregnancy.
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Figures (large format)
Figure 1
Pregnancy sera and placental factors augment the proportion of regulatory T (Treg) cells among peripheral blood mononuclear cells.
Effect of pregnancy sera and supernatant from early placental explants on the percentage of CD4+CD25+ T cells (A) or CD4+CD25+FOXP3+ T
cells (B) among peripheral blood mononuclear cells from healthy women (n = 4). Data are expressed as boxplots with whiskers from minimum to
maximum; the statistical analysis was performed using the Wilcoxon signed rank test. An asterisk indicates p <0.05.
Control = nonpregnant human serum; PS2 = pooled second trimester pregnancy sera; PS3 = pooled third trimester pregnancy sera; Plac =
supernatant from early placental explants
Figure 2
Induction of regulatory T (Treg) cells from CD4+CD25‒ T cells.
FACS staining after cell sorting. Cells are gated on CD4+ cells. The upper plot shows CD4+CD25‒FOXP3‒ T cells that were used at day 0 for
the induction assay. The lower plot shows the induction of CD4+CD25+FOXP3+ cells after 3 days’ exposure to supernatant from early placental
explants (A). Effect of pregnancy serum and supernatant from early or term placental explants on the percentage of CD4+CD25+ T cells (B) and
CD4+CD25+FOXP3+ T cells (C) in cell cultures with sorted CD4+CD25‒ T cells from healthy women (n = 6; for cultures with term placenta n =
2). Data are expressed as boxplots with whiskers from minimum to maximum and statistical analysis was performed using Wilcoxon signed rank
test. An asterisk indicates p <0.05.
Control = nonpregnant human serum; PS3 = pooled third trimester pregnancy sera; Plac early = supernatant from early placental explants; Plac
term = supernatant from term placental explants
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Figure 3
Effects of hormones on the proportion of regulatory T cells (Treg).
Effect of 17-oestradiol, oestriol and progesterone used at pregnancy levels on the proportion of Treg among PBMC (A) and CD4+CD25‒ T cells
(B) from healthy women (n = 4). Data are expressed as boxplots with whiskers from minimum to maximum and statistical analysis was
performed using Wilcoxon signed rank test.
Control = non-pregnant human serum; 17-Estrad = 17β-oestradiol; Prog = progesterone; 17-Estrad/Prog = combination of 17β-oestradiol and
progesterone; PBMC = peripheral blood mononuclear cell
Figure 4
Transforming growth factor-β (TGF-β) increases the proportion of regulatory T cells (Treg).
Displayed is the effect of increasing doses of TGF-β1 on the percentages of CD4+CD25+FOXP3+ and CD4+CD25+FOXP3- T cells among
PBMC of healthy women (n = 2). Data are expressed as dots, error bars representing mean ± SEM.
Control = nonpregnant human serum
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Figure 5
Cytokine secretion of regulatory T (Treg) cells induced by pregnancy serum or placental supernatant.
Cytokine concentrations (picograms per millilitre) in culture supernatants of Treg induced from sorted CD4+CD25‒ T cells of healthy donors in
the presence of pregnancy serum or supernatant from early or term placental explants. Statistical analysis was performed using Wilcoxon
signed rank test. Asterisk indicates p <0.05.
Control = non-pregnant human serum, PS3 = pooled third trimester pregnancy serum; Plac-early = supernatant of early placental explants;
Plac-term = supernatant of term placental explants: IFNγ = interferon-γ; IL = interleukin; TNFα = tumour necrosis factor-α
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Figure 6
Suppressive function of regulatory (Treg) T cells induced by soluble pregnancy factors.
Treg cells induced from CD4+CD25‒ T cells (iTreg) of two healthy donors in the presence of different soluble pregnancy factors were isolated
and used in a co-culture suppression assay with autologous CD4+CD25‒ T cells (Teff). iTreg and Teff cells cultured alone or in a 1:1 setting
were analysed for proliferation and for the suppressive capacity of Treg. Data are expressed as mean ± SEM.
Control = nonpregnant human serum; PS3 = pooled third trimester pregnancy serum; Plac = supernatant of early placental explants.
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